[1]杨雨桐,石磊,王秀丽.奥马珠单抗在皮肤科的应用[J].中国皮肤性病学杂志,2021,(09):1071-1075.[doi:10.13735/j.cjdv.1001-7089.202009120]
 YANG Yutong,SHI Lei,WANG Xiuli.Application of Omalizumab in Dermatology[J].The Chinese Journal of Dermatovenereology,2021,(09):1071-1075.[doi:10.13735/j.cjdv.1001-7089.202009120]
点击复制

奥马珠单抗在皮肤科的应用()
分享到:

《中国皮肤性病学杂志》[ISSN:1001-7089/CN:61-1197/R]

卷:
期数:
2021年09期
页码:
1071-1075
栏目:
继续医学教育
出版日期:
2021-09-01

文章信息/Info

Title:
Application of Omalizumab in Dermatology
文章编号:
1001-7089(2021)09-1071-05
作者:
杨雨桐石磊王秀丽
同济大学附属皮肤病医院,同济大学医学院光医学研究所,上海 200443
Author(s):
YANG YutongSHI LeiWANG Xiuli
(Institute of Photomedicine,Shanghai Skin Disease Hospital,Tongji University School of Medicine,Shanghai 200443,China)
关键词:
奥马珠单抗 荨麻疹 不良反应 临床应用
Keywords:
Omalizumab Urticarial Clinical application Adverse reaction
分类号:
R 751
DOI:
10.13735/j.cjdv.1001-7089.202009120
文献标志码:
A
摘要:
奥马珠单抗是一种新型生物制剂,本文对奥马珠单抗的作用机制、在皮肤科的应用和不良反应进行综述。奥马珠单抗可有效降低血清游离IgE水平,抑制过敏反应。慢性自发性荨麻疹作为奥马珠单抗目前在皮肤科唯一获批的适应症,其疗效和安全性已得到广泛认可。另外,奥马珠单抗在慢性诱导性荨麻疹中亦具有良好应用潜力,在特应性皮炎、系统性红斑狼疮、大疱性类天疱疮等其他皮肤疾病中也有成功应用的报道。在随机对照试验中,奥马珠单抗治疗与安慰剂相比不良反应发生率无明显差异。奥马珠单抗作用机制还有待完善,用药方案存在优化空间。
Abstract:
Omalizumab is a novel biological agent.This article reviews the mechanism,clinical applications and adverse reactions of omalizumab in the department of dermatology.Omalizumab suppresses allergic responses by reducing the level of serum free IgE.Aschronic spontaneous urticaria is currently the only approved indication for omalizumab in department of dermatology,its efficacy and safety have been widely recognized.Furthermore,omalizumab has high potential for application in chronic induced urticaria.Successful applications of omalizumab in atopic dermatitis,systemic lupus erythematosus,bullous pemphigoid and other skin diseases were reported as well.No significant difference was found in rates of adverse reactions between omalizumab and placebo group in randomized controlled trials.The mechanism of omalizumab needs to be improved and dosage regimens need to be optimized.

参考文献/References:

[1] Tonacci A,Nettis E,Asero R,et al.Omalizumab retreatment in patients with chronic spontaneous urticaria:a systematic review of published evidence [J].Eur Ann Allergy Clin Immunol,2020,52(3):100-103.
[2] 徐金华.中国荨麻疹诊疗指南(2018版)[J].中华皮肤科杂志,2019,52(1):1-5.
[3] Maurer M,Schütz A,Weller K,et al.Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial [J].J Allergy Clin Immunol,2017,140(3):870-873.
[4] Hasni S,Gupta S,Davis M,et al.Safety and tolerability of omalizumab:a randomized clinical trial of humanized anti-IgE monoclonal antibody in systemic lupus erythematosus[J].Arthritis Rheumatol,2019,71(7):1135-1140.
[5] Hinojosa T,Lewis DJ,Vangipuram R,et al.The efficacy of omalizumab in cutaneous mastocytosis:a case series [J].Dermatol Ther,2019,32(3):e12848.
[6] Basta F,Mazzuca C,Nucera E,et al.Omalizumab in eosinophilic granulomatosis with polyangiitis:friend or foe? A systematic literature review [J].Clin Exp Rheumatol,2020, 124(2):214-220.
[7] Yalcin AD.A case of netherton syndrome:successful treatment with omalizumab and pulse prednisolone and its effects on cytokines and immunoglobulin levels [J].Immunopharmacol Immunotoxicol,2016,38(2):162-166.
[8] Uzun R,Yalcin AD,Celik B,et al.Levofloxacin induced toxic epidermal necrolysis:successful therapy with omalizumab(anti-IgE)and pulse prednisolone [J].Am J Case Rep,2016(17):666-671.
[9] Zhao ZT,Ji CM,Yu WJ,et al.Omalizumab for the treatment of chronic spontaneous urticaria:A meta-analysis of randomized clinical trials [J].J Allergy Clin Immunol,2016,137(6):1742-1750.
[10] Hide M,Park Hs,Igarashi A,et al.Efficacy and safety of omalizumab in Japanese and Korean patients with refrac-tory chronic spontaneous urticaria [J].J Dermatol Sci,2017,87(1):70-78.
[11] Maurer M,Sofen H,Ortiz B,et al.Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria:analyses according to the presence or absence of angioedema [J].J Eur Acad Dermatol Venereol,2017,31(6):1056-1063.
[12] Mandel VD,Guanti MB,Liberati S,et al.Omalizumab in chronic spontaneous urticaria refractory to conventional therapy:an italian retrospective clinical analysis with suggestions for long-term maintenance strategies[J].Dermatol Ther(Heidelb),2018,8(2):291-301.
[13] Metz M,Schütz A,Weller K,et al.Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial [J].J Allergy Clin Immunol,2017,140(3):864-867.
[14] Aubin F,Avenel-Audran M,Jeanmougin M,et al.Omalizumab in patients with severe and refractory solar urti-caria:A phase II multicentric study [J].J Am Acad Dermatol,2016,74(3):574-575.
[15] Di Leo E,Calogiuri G,Macchia L,et al.Use of omali-zumab in uncontrolled chronic spontaneous urticaria also improved latex-induced contact urticaria [J].J Allergy Clin Immunol Pract,2019,7(1):300-302.
[16] Rorie A,Gierer S.A case of aquagenic urticaria successfully treated with omalizumab [J].J Allergy Clin Immunol Pract,2016,4(3):547-548.
[17] Maurer M,Metz M,Brehler R,et al.Omalizumab treatment in patients with chronic inducible urticaria:A systematic review of published evidence [J].J Allergy Clin Immunol,2018,141(2):638-649.
[18] Heil PM, Maurer D, Klein B, et al. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course-a randomized, placebo-controlled and double blind pilot study[J]. J Dtsch Dermatol Ges,2010,8(12): 990-998.
[19] Chan S,Cornelius V,Cro S,et al.Treatment effect of omalizumab on severe pediatric atopic dermatitis:the adapt randomized clinical trial[J].JAMA Pediatr,2020,174(1):29-37.
[20] Yu KK,Crew AB,Messingham KA,et al.Omalizumab therapy for bullous pemphigoid [J].J Am Acad Dermatol,2014,71(3):468-474.
[21] Ghazanfar MN,Thomsen SF.Omalizumab for urticarial vasculitis:case report and review of the literature [J].Case Rep Dermatol Med,2015,2015:576893.
[22] Aurich S,Simon JC,Treudler R.Omalizumab does not improve skin lesions in a patient with hypocomplementemic urticarial vasculitis syndrome [J].J Eur Acad Dermatol Venereol,2017,31(9):395-397.
[23] Namazy J,Cabana MD,Scheuerle AE,et al.The xolair pregnancy registry(EXPECT):the safety of omalizumab use during pregnancy [J].J Allergy Clin Immunol,2015,135(2):407-412.
[24] González-Medina M,Curto-Barredo L,Labrador-Horrillo M,et al.Omalizumab use during pregnancy for chronic spontaneous urticaria(CSU):report of two cases [J].J Eur Acad Dermatol Venereol,2017,31(5):245-246.
[25] Ensina LF,Cusato-Ensina AP,Camelo-Nunes IC,et al.Omalizumab as third-line therapy for urticaria during pregnancy [J].J Investig Allergol Clin Immunol,2017,27(5):326-327.
[26] Türk M,Carneiro-Leão L,Kolkhir P,et al.How to treat patients with chronic spontaneous urticaria with omalizumab:questions and answers[J].J Allergy Clin Immunol Pract,2020,8(1):113-124.
[27] Hughes JDM,Olynyc T,Chapdelaine H,et al.Effective management of severe cutaneous mastocytosis in young children with omalizumab(Xolair)[J].Clin Exp Dermatol,2018,43(5):573-576.
[28] 国家药品监督管理局药品评审中心.注射用奥马珠单抗[EB/OL].(2018-12-19)[2020-07-07] http://www.cde.org.cn/spxxgs.do?method=show&acceptidCode=ce14deba54ca237417b6ecf3f1613f93.

相似文献/References:

[1]王巧伟,王旭英,潘小川,等.北京地区环境空气污染物对荨麻疹日门诊人次的短期影响[J].中国皮肤性病学杂志,2016,(07):737.[doi:10.13735/j.cjdv.1001-7089.201508121]
 WANG Qiao-wei,WANG Xu-ying,PAN Xiao-chuan,et al.Short-term Effects of Ambient Air Pollution on Daily Outpatient Visits for Urticaria in Beijing[J].The Chinese Journal of Dermatovenereology,2016,(09):737.[doi:10.13735/j.cjdv.1001-7089.201508121]
[2]沈悦,张懿,徐晶,等.枸地氯雷他定联合甘草酸二胺治疗慢性荨麻疹66例临床观察[J].中国皮肤性病学杂志,2017,(08):933.[doi:10.13735/j.cjdv.1001-7089.201610048]
 SHEN Yue,ZHANG Yi,XU Jing,et al.Treatment of 66 Cases of Chronic Urticaria with Desloratadine Citrate Plus Diammonium Glycyrrhizinate[J].The Chinese Journal of Dermatovenereology,2017,(09):933.[doi:10.13735/j.cjdv.1001-7089.201610048]
[3]闫会昌,张江安,于建斌,等.Schnitzler综合征的临床特点[J].中国皮肤性病学杂志,2017,(09):1033.[doi:10.13735/j.cjdv.1001-7089.201609003]
 YAN Hui-chang,ZHANG Jiang-an,YU Jian-bin,et al.Clinical Features of Schnitzler Syndrome[J].The Chinese Journal of Dermatovenereology,2017,(09):1033.[doi:10.13735/j.cjdv.1001-7089.201609003]
[4]张禁,杨颜龙,姜功平,等.地氯雷他定联合复方甘草酸苷治疗慢性荨麻疹66例临床观察[J].中国皮肤性病学杂志,2013,(07):115.
 ZHANG Jin,YANG Yan-long,JIANG Gong-ping,et al.Observation of Clinical Efficency of Desloratadine Combined with Compound Glycyrrhizin in the Treatment of 66 Patients with Chronic Urticaria[J].The Chinese Journal of Dermatovenereology,2013,(09):115.
[5]陈文慧,李百灵,刘乐,等.苯磺贝他斯汀片联合卡介菌多糖核酸治疗慢性荨麻疹109例疗效观察[J].中国皮肤性病学杂志,2013,(10):111.
 CHEN Wen-hui,LI Bai-ling,LIU Le,et al.The Clinic Observation on the Efficacy of Bepotastine Besilate Plus BCG-PSN in the Treatment of 109 Cases of Chronic Urticaria[J].The Chinese Journal of Dermatovenereology,2013,(09):111.
[6]陈文慧,刘乐,赵玢,等.盐酸奥洛他定联合曲尼司特治疗慢性荨麻疹疗效观察[J].中国皮肤性病学杂志,2019,(06):734.[doi:10.13735/j.cjdv.1001-7089.201804019]
 CHEN Wenhui,LIU Le,ZHAO Bin,et al.Clinical Observation of Olopatadine Hydrochloride Combined with Tranilast in the Treatment of Chronic Urticaria[J].The Chinese Journal of Dermatovenereology,2019,(09):734.[doi:10.13735/j.cjdv.1001-7089.201804019]
[7]吕超,胡小平,于波,等.瘤型麻风误诊1例分析[J].中国皮肤性病学杂志,2019,(07):851.[doi:10.13735/j.cjdv.1001-7089.201806013]
 LYU Chao,HU Xiaoping,YU Bo,et al.Analysis of a Case of Misdiagnosed Lepromatous Leprosy[J].The Chinese Journal of Dermatovenereology,2019,(09):851.[doi:10.13735/j.cjdv.1001-7089.201806013]
[8]白瑶,石春蕊,董继元,等.兰州市区SO2、NO2浓度对荨麻疹日门诊人次的影响[J].中国皮肤性病学杂志,2020,(06):704.[doi:10.13735/j.cjdv.1001-7089.201906053]
 BAI Yao,SHI Chunrui,DONG Jiyuan,et al.Effects of SO2 and NO2 Concentration on the Number of Daily Outpatient Visits for Urticaria in Lanzhou[J].The Chinese Journal of Dermatovenereology,2020,(09):704.[doi:10.13735/j.cjdv.1001-7089.201906053]

备注/Memo

备注/Memo:
[基金项目] 国家自然科学基金面上项目(81872212); 上海市静安区领军人才项目
[通信作者] 王秀丽,E-mail:wangxiuli_1400023@tongji.edu.cn
更新日期/Last Update: 2021-09-01